Table 1.
Patients’ characteristics
| Variable | N = (174) |
|---|---|
| Age (years) | 70.5 (11.4) |
| Gender (female) | 42.0% (73) |
| Complication in the first 28 postoperative days | 18.4% (32) |
| Anesthetic agent (N = 166) | |
| Halogenated | 75.3% (125) |
| Intravenous | 20.5% (34) |
| Both | 4.2% (7) |
| Intraoperative remifentanil perfusion (N = 169) | 47.9% (81) |
| First postoperative 96 h total opioid dose | 76.43 (34.76) |
| Intraoperative epidural analgesia (Yes) | 16.1% (28) |
| Red blood cell transfusion in the first postoperative 96 h | 30.5% (53) |
| CEA value at diagnosis (N = 163) (U∙mL−1) | 2.60 [1.60–5.10] |
| Surgical duration (min) | 217.52 (88.22) |
| Preoperative total proteins (g∙dL−1) | 7.00 [6.00–7.00] |
| Preoperative Hemoglobin value (g∙dL−1) | 12.03 (2.07) |
| Number of affected lymph nodes | 0 [0–2] |
| Preoperative chemotherapy (Yes) | 10.3% (18) |
| Preoperative radiotherapy (Yes) | 9.8% (17) |
| Postoperative chemotherapy (Yes) | 50.0% (87) |
| Postoperative radiotherapy (Yes) | 1.7% (3) |
| ASA score (N = 157) | |
| 1 | 7.6% (12) |
| 2 | 54.8% (86) |
| 3 | 33.8% (53) |
| 4 | 3.8% (6) |
| HTA (Yes) | 54.6% (95) |
| Diabetes Mellitus (Yes) | 19.5% (34) |
| Reintervention Yes) | 6.3% (11) |
| Readmission (Yes) | 3.4% (6) |
| Dukes (N = 153) | |
| A | 1.3% (2) |
| B | 51.0% (78) |
| C | 46.4% (71) |
| D | 1.3% (2) |
| Cancer Staging (III) | 44.8% (78) |
| Ca 19–9 value at diagnosis (U∙mL−1) (N = 124) | 11.1 [5.3–18.5] |
| Resection margins (R+) (N = 135) | 19% (25) |
| Tumoral tissue differentiation (N = 169) | |
| Poor/Undifferentiated | 12.0% (20) |
| Moderately differentiated | 78% (132) |
| Well differentiated | 10.0% (17) |
Values are reported as mean (standard deviation) or percentage (N) or median [25th–75th percentile] as appropriate. HTA: Arterial hypertension; CEA: Carcinoembryonic antigen; ASA: American Society of Anesthesiology; Ca 19-9: Carbohydrate antigen 19-9; R+: Positive resection margin.